A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication

Journal of Korean Medical Science

Volumn 19, Issue 5, 2004, Pages 750-752

  Lee, Soo Youn ^a   Ki, Chang Seok ^a   Kyung, Sue Hong ^a   Jong, Won Kim ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Adverse effects; Cytochrome P 450 CYP2D6; Nortriptyline; Pharmacogenetics

Indexed keywords

CYTOCHROME P450 2D6; LORAZEPAM; NORTRIPTYLINE; RISPERIDONE;

ADULT; ANXIETY; ARTICLE; CASE REPORT; CATALYSIS; CONSTIPATION; DELUSION; DIZZINESS; DRUG BLOOD LEVEL; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME METABOLISM; GENE AMPLIFICATION; GENOTYPE; HEMOCONCENTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INSOMNIA; MAJOR DEPRESSION; MALE; PHYSICAL EXAMINATION; PSYCHOSIS; PSYCHOTHERAPY; SUICIDE ATTEMPT; TOXICITY; XEROSTOMIA;

EID: 7544234883     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2004.19.5.750     Document Type: Article

References (15)

1. Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 1993; 54: 14-34.
2. Linder MW, Keck PE Jr. Standards of laboratory practice: antidepressant drug monitoring. Clin Chem 1998; 44: 1073-84.
3. Morita S, Shimoda K, Someya T, Yoshimura Y, Kamijima K, Kato N. Steady state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: Impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J Clin Psychopharmacol 2000; 20: 141-9.
4. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53: 111-22.
5. Dahl ML, Bertilsson L, Nordin C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology 1996; 123: 315-9.
6. Dalen P, Dahl ML, Ruiz ML, Nordin J, Bertilsson L. W-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3 and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63: 444-52.
7. Bertilsson L, Mellstrorn B, Sjokvist F, Martension B, Asberg M. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications: letter. Lancet 1981; 1: 560-1.
8. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989; 45: 889-94.
9. Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E. Rapid detection of the CYP2D6*3, CYP2D6*4, CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 2000; 46: 1072-7.
10. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3: 229-43.
11. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan o-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 2000; 50: 31-4.
12. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996; 6: 441-7.
13. Shim JC, Gong B, Park JH, Yoon YR, Sin JG, Kim JI, Ann DS, Kim YK, Cha IJ, Kim YH. Combined therapy of paroxetine and tricyclic antidepressant in depression of schizophrenic patients. J Korean Neuropsychiatr Assoc 1997; 36: 732-41.
14. DeVane CL, Nemeroff CB. An evaluation of risperidone drug interactions. J Clin Psychopharmacol 2001; 21: 408-16.
15. Franssen EJ, Kunst PW, Bet PM, Strack van Schijndel RJ, van Loenen AC, Wilhelm AJ. Toxicokinetics of nortriptyline and amitriptyline: two case reports. Ther Drug Monit 2003; 25: 248-51.